| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 103.98 | 43.9% |
| Total Income | 106.18 | 41.2% |
| Expenditure | 114.48 | 41.8% |
| PBT | -8.30 | 50.9% |
| Net Profit | -9.44 | 19.9% |
| OPM | 2.15% | 30.58pp |
| NPM | -8.89% | 1.57pp |
| EPS | 14.40 | 244.0% |
Bharat Parenterals Ltd Reports 19.8% Standalone Revenue Growth in FY25, Despite Consolidated Loss of INR 43.7 Crores
13 May 2025 · 13 May 2025, 12:36 am
Summary
Bharat Parenterals Ltd (BPL) reported a 19.8% increase in standalone revenue from operations in FY25, reaching INR 318.7 crores. However, on a consolidated basis, BPL reported a loss of INR 43.7 crores due to increased operating expenses. The company's gross profit rose from INR 107.5 crores in FY24 to INR 166.8 crores in FY25. Innoxel Lifesciences, BPL’s subsidiary, continued to advance its pipeline of complex and specialty injectable products for regulated markets.
Key Highlights
- 1
Standalone revenue growth of 19.8% in FY25
- 2
Consolidated loss of INR 43.7 crores in FY25
- 3
Gross profit rise from INR 107.5 crores in FY24 to INR 166.8 crores in FY25
- 4
Innoxel Lifesciences' pipeline advancement in regulated markets
- 5
USFDA successful inspection of Innoxel’s Vadodara facility in Q4FY25
Management Comments
Not Specified
BPL continued to build on its strong foundation in pharmaceutical manufacturing during FY25, delivering robust revenue growth, improving operating metrics at the standalone level, and laying long-term groundwork through strategic investments in its complex generic’s subsidiary, Innoxel Lifesciences.
Informational and educational content only. Not investment advice.